Novartis Invests $7.5M to Promote Early Prostate Cancer Testing in Vulnerable Communities
Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for ...
Pharm Exec3d
Novartis Commits $75 Million to ZERO Prostate Cancer Initiative
According to ZERO Prostate Cancer, Novartis has committed $7.5 million to the initiative.
FiercePharma5d
Novartis pumps $7.5M into push to save 100,000 lives from prostate cancer by 2035
Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...
Big pharma sues GenesisCare over Labor-endorsed copycat cancer drug
Swiss pharma giant Novartis is taking legal action against the Australian cancer care provider as a dispute over how to fund ...
Yahoo Finance6d
ZERO Prostate Cancer Launches Bold $20 Million 'Blitz The Barriers' Initiative to Close Gaps in Prostate Cancer Survival in Highest-Risk Communities
Novartis, an innovative medicines company, will launch Blitz the Barriers. ZERO will activate in Atlanta and Baltimore, pilot cities with significant disparities in prostate cancer health outcomes ...
Photodynamic Therapies in Oncology Market is Predicted to Exhibit Remarkable Growth During the Study Period (2020–2034) | DelveInsight
The market for PDTs in oncology is projected to experience substantial growth in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NMSCs, ovarian ...
Targeted Oncology6d
Relugolix Shows Strong Adherence in Medicare Patients With Prostate Cancer
Over 90% adherence to relugolix in patients with Medicare with prostate cancer for 24 months supports its use as androgen ...